entertainment -WSS

entertainment

author：fashion 2025-09-30 22:10:46 - browse：6

Alnylam headquarters — Kristoffer Tripplaar/Sipa USA/AP

A group of advisers to the Food and Drug Administration voted in favor of Alnylam Pharmaceuticals’ treatment for a debilitating heart disease Wednesday, but only after a day-long debate challenging whether the drug’s modest observed effects were actually meaningful for patients.

The group of independent experts voted 9-3 that the benefits of Alnylam’s drug, called patisiran, outweighed its risks for patients with ATTR-CM, a progressive disease that leads to fatal heart failure if left untreated. The FDA, which is not required to follow the advice of advisers, is expected to make a final decision on patisiran by Oct. 8.

“It’s like a light wind blowing in favor of patisiran over placebo,” said David Cella, a neurologist at the Northwestern University Feinberg School of Medicine who voted in favor of patisiran. David Moliterno, a cardiologist at the University of Kentucky, added that “the good news in this story is that while there may be a small benefit, it doesn’t look like there’s a signal for harm.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： A Theranos scientist

focus

WSS

First transplant of an entire human eye performed

DeSantis says Trump could've 'come out more forcefully' during Jan. 6

NIH chief: government has fallen behind pharma on clinical trials

Readout Newsletter: Zepbound, Valneva's vaccine, and more

Phoenix breaks record with 19 consecutive days above 110 degrees Fahrenheit

ER docs worry over extreme heat as a 'mass casualty event'

focus

entertainment

focus

Tori Bowie and the unacceptable rates of Black maternal death

A letter from the executive editor: STAT UnitedHealth investigation

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

A letter from the executive editor: STAT UnitedHealth investigation

Medicare details structure of new drug price negotiation program

Flagship, Pfizer team up in deal worth up to $7 billion

Medical leaders decry Supreme Court decision on affirmative action

Medicare’s new pay boost for primary care is angering specialists

Malaria cases in Florida and Texas: Here’s what you need to know

Ventyx halts psoriasis drug development after lackluster trial results

focus

15 die by electrocution after transformer explodes in northern India

Twill hunts for pharma partner to market its depression app

Biden administration sends mixed signals on US soldier who crossed into North Korea

What health policies could hitch a ride on a spending bill?

Asa Hutchinson previews new plan to reform federal law enforcement if elected in 2024

Study: Hearing aids may slow cognitive decline in those at risk

hotspot

entertainment

focus

Wikipedia